Payment overview · 2025
General Payments
$141.17
9 reported records · 7 companies
Healthcare provider profile · identity verified
Darby Cole, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OWENSBORO, KY · NPI 1306838693
Verified facts
What the public records show
CMS Open Payments records show Darby Cole, M.D. received $141.17 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.03 | 35.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.15 | 12.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.08 | 11.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.46 | 10.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $14.42 | 10.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.29 | 10.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.74 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.17 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
55 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 250 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 36 |
| Potassium Chloride | Potassium Chloride | 181 | 28 |
| Furosemide | Furosemide | 165 | 31 |
| Lisinopril | Lisinopril | 147 | 35 |
| Sertraline Hcl | Sertraline Hcl | 132 | 22 |
| Metformin Hcl | Metformin Hcl | 124 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 24 |
| Eliquis | Apixaban | 108 | 14 |
| Simvastatin | Simvastatin | 107 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 27 |
| Carvedilol | Carvedilol | 97 | 22 |
| Omeprazole | Omeprazole | 94 | 17 |
| Losartan Potassium | Losartan Potassium | 92 | 23 |
| Buspirone Hcl | Buspirone Hcl | 91 | 11 |
| Allopurinol | Allopurinol | 86 | 12 |
| Trazodone Hcl | Trazodone Hcl | 86 | 14 |
| Gabapentin | Gabapentin | 75 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 11 |
| Metformin Hcl Er | Metformin Hcl | 67 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 17 |
| Spironolactone | Spironolactone | 64 | suppressed |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Pregabalin | Pregabalin | 61 | suppressed |
| Baclofen | Baclofen | 60 | suppressed |
| Mirtazapine | Mirtazapine | 60 | suppressed |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 39 |
| Sucralfate | Sucralfate | 55 | suppressed |
| Ezetimibe | Ezetimibe | 54 | suppressed |
| Jardiance | Empagliflozin | 52 | 11 |
| Atenolol | Atenolol | 51 | 14 |
| Risperidone | Risperidone | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Meloxicam | Meloxicam | 48 | 16 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Enulose | Lactulose | 41 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | suppressed |
| Ozempic | Semaglutide | 33 | 11 |
| Topiramate | Topiramate | 32 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Premarin | Estrogens, Conjugated | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Lactulose | Lactulose | 25 | 20 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.17 · 9 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, Kerendia, LEQVIO, PREVNAR 20, SHINGRIX, SKYCLARYS, SPRAVATO | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error